Tirzepatide vs AOD-9604
Side-by-side comparison of Tirzepatide, AOD-9604 — mechanism, dosing, half-life, side effects, and research status.
| Attribute | Tirzepatide Tirzepatide (GIP/GLP-1 Dual Agonist) Weight Loss | AOD-9604 hGH Fragment 176-191 (Anti-Obesity Drug 9604) Weight Loss |
|---|---|---|
| Basics | ||
| Molecular type | Dual GIP/GLP-1 Receptor Agonist | hGH C-terminal Fragment |
| Amino acids | 39 | 16 |
| Molecular weight | 4,813.5 Da | 1,815.1 Da |
| Half-life | ~5 days | ~30 min |
| Route(s) | Subcutaneous injection | Subcutaneous, Oral (research) |
| Mechanism & Research | ||
| Primary mechanism | Tirzepatide's dual mechanism differentiates it from pure GLP-1 agonists. The GIP component contributes additional appetite suppression via hypothalamic GIP receptors and improves insulin secretion efficiency. The two inc… | AOD-9604 mimics the lipolytic (fat-breaking) action of the C-terminal fragment of growth hormone at the beta-3 adrenergic receptor in adipocytes. By activating beta-3 receptors, it promotes lipolysis (fat cell triglyceri… |
| Research status | FDA Approved | Research Compound |
| Evidence summary | Tirzepatide's clinical development programme (SURPASS for diabetes, SURMOUNT for obesity) has consistently demonstrated superior weight loss outcomes to comparator GLP-1 agonists. The SURMOUNT-1 trial set a new benchmark… | AOD-9604 completed Phase 2b trials for obesity (METRO study) before development was discontinued. Despite clear mechanistic rationale and positive preclinical data, the Phase 2b trial did not demonstrate statistically si… |
| Protocol & Dosing | ||
| Typical dose | 2.5mg → 15mg weekly | 300–500 mcg/day |
| Frequency | Once weekly | Once daily |
| Duration | Ongoing (chronic) | 8–12 weeks |
| Timing | Same day each week, any time of day | Pre-workout or morning on empty stomach (for metabolic effects) |
| Safety | ||
| Common side effects |
|
|
| Contraindications |
|
|
| Anti-doping | Not Prohibited | Prohibited (WADA S2) |
| Deeper reading | ||
| Related peptides | Semaglutide, AOD-9604, Tesamorelin | Semaglutide, Ipamorelin, Tesamorelin |
| Full profile | Read full Tirzepatide profile → | Read full AOD-9604 profile → |
Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.